| Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia V Madan, P Shyamsunder, L Han, A Mayakonda, Y Nagata, ... Leukemia 30 (8), 1672-1681, 2016 | 161 | 2016 |
| Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia Q Zhang, B Riley-Gillis, L Han, Y Jia, A Lodi, H Zhang, S Ganesan, R Pan, ... Signal transduction and targeted therapy 7 (1), 51, 2022 | 115 | 2022 |
| Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy E Chendamarai, P Balasubramanian, B George, A Viswabandya, ... Blood, The Journal of the American Society of Hematology 119 (15), 3413-3419, 2012 | 79 | 2012 |
| Comparison of Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide: Insight into Mechanisms of Resistance PLoS One 10 (3), e0121912., 2015 | 45 | 2015 |
| Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia S Ganesan, AA Alex, E Chendamarai, N Balasundaram, HK Palani, ... Leukemia 30 (11), 2169-2178, 2016 | 44 | 2016 |
| Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths M Cortés-López, P Chamely, AG Hawkins, RF Stanley, AD Swett, ... Cell Stem Cell 30 (9), 1262-1281. e8, 2023 | 40 | 2023 |
| Stromal cells downregulate miR-23a-5p to activate protective autophagy in acute myeloid leukemia S Ganesan, HK Palani, V Lakshmanan, N Balasundaram, AA Alex, ... Cell death & disease 10 (10), 736, 2019 | 38 | 2019 |
| Single-cell multi-ome and immune profiles of the Inspiration4 crew reveal conserved, cell-type, and sex-specific responses to spaceflight JK Kim, BT Tierney, EG Overbey, E Dantas, M Fuentealba, J Park, ... Nature Communications 15 (1), 4954, 2024 | 27 | 2024 |
| Management of relapse in acute promyelocytic leukaemia treated with up‐front arsenic trioxide‐based regimens NA Fouzia, V Sharma, S Ganesan, HK Palani, N Balasundaram, S David, ... British journal of haematology 192 (2), 292-299, 2021 | 24 | 2021 |
| Mapping genotypes to chromatin accessibility profiles in single cells F Izzo, RM Myers, S Ganesan, L Mekerishvili, S Kottapalli, T Prieto, ... Nature 629 (8014), 1149-1157, 2024 | 23 | 2024 |
| A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide U Kulkarni, S Ganesan, AA Alex, H Palani, S David, N Balasundaram, ... Cancer Medicine 9 (8), 2603-2610, 2020 | 22 | 2020 |
| Combination lenalidomide/bortezomib treatment synergistically induces calpain-dependent ikaros cleavage and apoptosis in myeloma cells S Ganesan, HK Palani, N Balasundaram, S David, AJ Devasia, B George, ... Molecular Cancer Research 18 (4), 529-536, 2020 | 22 | 2020 |
| Microenvironment and drug resistance in acute myeloid leukemia: do we know enough? S Ganesan, V Mathews, N Vyas International Journal of Cancer, 2021 | 20 | 2021 |
| Arsenic trioxide enhances the NK cell cytotoxicity against acute promyelocytic leukemia while simultaneously inhibiting its bio-genesis AA Alex, S Ganesan, HK Palani, N Balasundaram, S David, KM Lakshmi, ... Frontiers in Immunology 9, 1357, 2018 | 19 | 2018 |
| Prevalence of FVIII inhibitors in severe haemophilia A patients: Effect of treatment and genetic factors in an Indian population S David, SC Nair, GS Singh, AA Alex, S Ganesan, HK Palani, ... Haemophilia 25 (1), 67-74, 2019 | 16 | 2019 |
| Integrated Single-Cell Genotyping and Chromatin Accessibility Charts JAK2V617F Human Hematopoietic Differentiation RM Myers, F Izzo, S Kottapalli, T Prieto, A Dunbar, RL Bowman, ... biorxiv, 2022.05. 11.491515, 2022 | 15 | 2022 |
| BCL-2 inhibitor ABT-737 effectively targets leukemia-initiating cells with differential regulation of relevant genes leading to extended survival in a NRAS/BCL-2 mouse model of … P Gorombei, F Guidez, S Ganesan, M Chiquet, A Pellagatti, L Goursaud, ... International journal of molecular sciences 22 (19), 10658, 2021 | 13 | 2021 |
| T-cell protein tyrosine phosphatase is irreversibly inhibited by etoposide-quinone, a reactive metabolite of the chemotherapy drug etoposide Q Nian, J Berthelet, W Zhang, LC Bui, R Liu, X Xu, R Duval, S Ganesan, ... Molecular pharmacology 96 (2), 297-306, 2019 | 11 | 2019 |
| JAK inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms N Maslah, B Roux, N Kaci, E Verger, R Daltro De Oliveira, H Pasquer, ... Blood 140 (Supplement 1), 795-796, 2022 | 9 | 2022 |
| Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia N Balasundaram, S Ganesan, E Chendamarai, HK Palani, ... Blood advances 6 (2), 652-663, 2022 | 9 | 2022 |
Vikram MathewsProfessor of Clinical HematologyПотвърден имейл адрес: cmcvellore.ac.in